title: [Investigation of FOLFIRI/FOLFOX (+/-bevacizumab) therapy for patients with metastatic colorectal cancer in our hospital].
abstract: Bevacizumab has been demonstrated to prolong survival in patients with metastatic colorectal cancer when used in combination with chemotherapy. We investigated the efficacy of chemotherapy administered in our general hospital for patients with metastatic colorectal cancer after the introduction of FOLFOX/FOLFIRI (+/-bevacizumab) therapy.
  
  
  METHODS
  The subjects in this study were 34 patients diagnosed with metastatic colorectal cancer, who received either FOLFIRI (+/- bevacizumab) or mFOLFOX6 (+/-bevacizumab) therapy in this hospital. The subjects were divided into a bevacizumab combination regimen group (those who received the regimen as first-line treatment), and a non-bevacizumab combination regimen group (those who did not receive the regimen as first-line treatment). Comparisons were made with regard to anticancer efficacy, progression-free survival time, and overall survival time.
  
  
  RESULTS
  Comparison between the bevacizumab combination regimen group and the non-bevacizumab combination regimen group, revealed no significant difference due to the small number of relevant patients. However, the former showed a slight advantage over the latter in terms of anti-cancer efficacy and progression-free survival time.
  
  
  CONCLUSIONS
  Bevacizumab is expected to contribute to the prolongation of survival in patients in our general hospital.
authors.affiliation: Dept. of Surgery, Ohtawara Red-Cross Hospital.
authors.forename: Kei
authors.initials: K
authors.lastname: Hosoda
authors.forename: Masahiko
authors.initials: M
authors.lastname: Aoki
authors.forename: Hiromu
authors.initials: H
authors.lastname: Kido
authors.forename: Kingen
authors.initials: K
authors.lastname: Natsu
authors.forename: Hikaru
authors.initials: H
authors.lastname: Tamura
authors.forename: Masao
authors.initials: M
authors.lastname: Kojima
authors.forename: Tetsu
authors.initials: T
authors.lastname: Amemiya
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kamoshida
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006769:Hospitals, General; D006779:Hospitals, Public; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin